首页> 外文OA文献 >191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

【2h】

191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

机译：191系：神秘主义者：全球性，第3阶段对Durvalumab（Medi4736）的三相研究加上Tremetimumab组合治疗或Durvalumab单疗法与铂金疗法（CT）在先进的阶段IV NSCLC治疗患者（PTS）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
S. Peters; S. Antonia; S.B. Goldberg; J.V. Heymach; E.S. Kim; K. Nakagawa; V. Papadimitrakopoulou; P. Mukhopadhyay; S. McIntosh; N.A. Rizvi;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC [J] . Naiyer Rizvi, Fabrice Barlesi, Julie Brahmer, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：晚期，转移性NSCLC患者一线治疗中的durvalumab（MEDI4736）联合tremelimumab或durvalumab单独与铂类化疗联合进行的III期随机开放标签研究：MYSTIC
2. P2.06-022 First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study [J] . Tony Mok, Peter Schmid, Gilberto De Castro, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P2.06-022第一线Durvalumab Plus Tremelimumab对高级/转移NSCLC的基于铂化疗：第3阶段海王星研究
3. P2.06-022 First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study [J] . Tony Mok, Peter Schmid, Gilberto De Castro, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P2.06-022第一线Durvalumab Plus Tremelimumab对高级/转移NSCLC的基于铂化疗：第3阶段海王星研究
4. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
5. Phase III randomized open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC [O] . Naiyer Rizvi, Fabrice Barlesi, Julie Brahmer, 2015

机译：晚期转移性NSCLC患者一线治疗中的durvalumab（MEDI4736）联合tremelimumab或durvalumab单独与铂类化疗联合进行的III期随机开放标签研究：MYSTIC
6. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC [O] . Naiyer Rizvi, Fabrice Barlesi, Julie Brahmer, 2015

机译：晚期，转移性NSCLC患者一线治疗中的durvalumab（MEDI4736）联合tremelimumab或durvalumab单独与铂类化疗联合进行的III期随机开放标签研究：MYSTIC
7. Studies of Ocular Complications of AIDS (SOCA): Database Documentation for'Combination Foscarnet and Ganciclovir Therapy versus Monotherapy for the Treatment of Relapsed Cytomegalovirus Retinitis in Patients with AIDS (CRRT)' [R] . 1997

机译：艾滋病眼部并发症（sOCa）研究：“联合膦甲酸和更昔洛韦治疗与单药治疗艾滋病患者复发性巨细胞病毒性视网膜炎（CRRT）”的数据库文件

191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

著录项

相似文献

相关主题

期刊订阅